Quanterix - QTRX Stock Forecast, Price & News

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cowen lowered Quanterix from an "outperform" rating to a "market perform" rating in a research note on Tuesday. The Goldman Sachs Group lowered their price objective on Quanterix from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Thursday, July 14th. SVB Leerink lowered Quanterix from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $35.00 to $15.00 in a research note on Tuesday. Finally, Cowen lowered Quanterix from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $38.00 to $18.00 in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $31.20.

Quanterix Stock Performance

Shares of NASDAQ:QTRX opened at $7.46 on Wednesday. The business's 50 day moving average price is $17.03 and its 200-day moving average price is $23.03. Quanterix has a fifty-two week low of $6.31 and a fifty-two week high of $60.92. The company has a market cap of $275.35 million, a price-to-earnings ratio of -4.14 and a beta of 1.46.

Quanterix (NASDAQ:QTRX - Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.18. Quanterix had a negative return on equity of 14.70% and a negative net margin of 58.23%. The firm had revenue of $29.55 million for the quarter, compared to the consensus estimate of $28.62 million. Sell-side analysts predict that Quanterix will post -2.49 earnings per share for the current year.